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Abstract
Background: Neuropathic pain is a common complication of treatment
with the anti-neoplastic drug paclitaxel. Animal studies suggest
neuroinflammation and transient receptor potential channels TRPA1 and
TRPV4 are involved in the pathogenesis of pain in this condition. However,
how neuroinflammation and TRPA1 and TRPV4 are linked to cause pain in
paclitaxel-treated animals is not known.
Methods: Paclitaxel-induced pain was modelled by IP injection of
paclitaxel (16 mg/kg) once a week for 5 weeks. The role of toll-like
receptor 4 (TLR-4) in tumour necrosis factor-α (TNF-α) production and
the effect of TNF-α on the expression of TRPA1 and TRPV4 were evaluated
in vitro and in vivo. TNF-α signalling in dorsal root ganglion (DRG) was
blocked by expressing soluble TNF receptor I (TNFsR) from a herpes
simplex virus (HSV)-based vector (vTNFsR).
Results: Paclitaxel treatment increased the expression and release of
TNF-α in satellite glial cells and increased the expression of TRPA1 and
TRPV4 in DRG neurons in animals. In vitro, paclitaxel enhanced the
expression and release of TNF-α in enriched primary satellite glial cells, an
effect that was blocked by an inhibitor of TLR-4. Direct application of
TNF-α to primary DRG neurons in culture up-regulated the expression of
TRPA1 and TRPV4. In vivo, vector-mediated TNFsR release from DRG
neurons reduced paclitaxel-induced up-regulation of TRPA1 and TRPV4
expression and prevented paclitaxel-induced pain.
Conclusion: These results suggest that paclitaxel activation of TLR-4 to
cause release of TNF-α from satellite glial cells increases the expression of
TRPA1 and TRPV4 in DRG neurons to cause neuropathic pain.
1. Introduction
Paclitaxel is a widely used anti-neoplastic agent and
neuropathic pain is a common complication of the
drug that not infrequently requires alteration in the
treatment schedule or termination of the treatment
(Dougherty et al., 2004). Paclitaxel-induced neuro-
pathic pain is characterized by hypersensitivity to
mechanical and cold stimuli that begins early after the
initiation of treatment and may persist weeks or years
after termination of the therapy (Dougherty et al.,
2004).
Chronic pain and impairment in sensory nerve
function are observed in cancer patients receiving
paclitaxel treatment (Dougherty et al., 2004). But pre-
clinical studies suggest that paclitaxel-induced pain is
mechanistically independent of peripheral neuropa-
thy: (1) paclitaxel induces pain at a dose that does not
significantly alter sensory nerve function measured by
electrophysiological testing (Flatters and Bennett,
2006); and (2) pain emerges long before deficits in
sensory nerve function in patients, or in animals
treated with a high-dose paclitaxel (Authier et al.,
2000; Dougherty et al., 2004).
© 2014 European Pain Federation - EFIC Eur J Pain 19 (2015) 889--898 889
There is indirect evidence for a role of neuroinflam-
mation in the development of paclitaxel-induced pain.
Pain-related behaviours in paclitaxel-treated animals
are reduced by the anti-inflammatory agent thalido-
mide, the microglia activation inhibitor minocycline or
by the anti-inflammatory cytokine IL10 (Ledeboer
et al., 2007; Cata et al., 2008), and the production of
tumour necrosis factor-α (TNF-α), a key mediator of
inflammation, is inhibited by these treatments
(Ledeboer et al., 2007; Cata et al., 2008). The first aim
of the current study was to directly evaluate the role of
TNF-α in the pathogenesis of paclitaxel-induced pain.
In tissue culture, paclitaxel has been shown to be a
ligand for the toll-like receptor 4 (TLR-4), causing
LPS-like activation of the TLR-4 receptor to induce
production of pro-inflammatory cytokines including
TNF-α (Byrd-Leifer et al., 2001). In addition to its role
in innate immunity, TLR-4 has been shown to partici-
pate in the pathogenesis of neuropathic pain in other
models of nerve injury (Bettoni et al., 2008; Wu et al.,
2010). TLR-4 is constitutively expressed in both satel-
lite glial cells and neurons in dorsal root ganglia (DRG)
(Barajon et al., 2009) and paclitaxel accumulates in
DRG after administration (Cavaletti et al., 2000). The
second aim of this study was to investigate how pacli-
taxel induces TNF-α expression by examining the role
of TLR-4 activation in TNF-α expression and cleavage.
Both TRPA1 and TRPV4 contribute to paclitaxel-
induced mechanical allodynia (Alessandri-Haber
et al., 2004) while TRPA1 is critical for paclitaxel-
induced cold allodynia (Chen et al., 2011; Materazzi
et al., 2012). The third aim of the current study was to
examine the effect of blocking TNF-α signalling on the
expression of these two cation channels in paclitaxel-
treated animals in order to understand how TNF-α
signalling might lead to paclitaxel-induced pain.
2. Materials and methods
2.1 Experimental animals
Male Sprague-Dawley rats weighing 250–300 g were used in
these experiments. Animals were housed 2 per cage for 1
week before use under a light/dark (12:12 h) cycle and pro-
vided with food and water ad libitum. All procedures were
performed using protocols approved by the Institutional
Animal Care and Use Committee.
2.2 Reagents
Recombinant rat TNF-α (R&D Systems, Minneapolis, MN,
USA), which contains the soluble extracellular portion
(sTNF-α) of rat TNF-α (amino acids 80–235) (Mohan et al.,
2002), was used in vitro studies. TLR-4 inhibitor TAK-242
(InvivoGen, San Diego, CA, USA) was suspended in DMSO
(Thermo Scientific, Rockford, IL, USA) to make 3 mM stock
and diluted to a working concentration (3 μM) in culture
medium (Kawamoto et al., 2008).
2.3 Paclitaxel administration
Paclitaxel (6 mg/mL in 50:50 cremophor EL/ethanol) was
purchased from Bristol-Myers Squibb (Princeton, NJ, USA)
and diluted to 2 mg/mL with saline just before use. Animals
were injected with paclitaxel (16 mg/kg, IP) once a week for
5 weeks to model paclitaxel-induced painful peripheral neu-
ropathy (Authier et al., 2000). Cremophor EL/ethanol
(50:50) diluted threefold with saline was used as the vehicle
control.
2.4 Vector injection
The replication-defective herpes simplex virus (HSV)-based
vector (vTNFsR), which expresses soluble TNF receptor I
(TNFsR) under the regulatory control of the HSV ICP0
immediate-early promoter (Peng et al., 2006; Hao et al.,
2007), was used to block TNF-α signalling in animals.
vTNFsR or control vector expressing green fluorescent
protein constructed in the same HSV backbone (3 × 108
plaque forming units in 30 μL PBS) was injected subcutane-
ously into the plantar surface of both hind paws twice. The
vectors were injected 3 days before the first dose of pacli-
taxel, and a repeat injection was performed 2 weeks later.
2.5 TNFsR release from DRG neurons
of animals
Three days after vector injection, L4-6 DRGs from both sides
of each animal were dissected, prepared as previously
What’s already known about this topic?
• Transient receptor potential channels TRPA1 and
TRPV4 both contribute to paclitaxel-induced
mechanical allodynia.
• TRPA1 is responsible for paclitaxel-induced cold
allodynia.
• Immunoactivation of sensory neurons plays a
role in the pathogenesis of paclitaxel-induced
neuropathic pain.
What does this study add?
• Paclitaxel induces tumour necrosis factor-α
(TNF-α) production in satellite glial cells of the
dorsal root ganglion (DRG) through activation of
toll-like receptor 4.
• TNF-α mediates paclitaxel-induced neuropathic
pain by up-regulating the expression of TRPA1
and TRPV4 in DRG neurons.
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described (Wu et al., 2005), seeded into wells of a 12-well
plate and cultured in Neurobasal medium supplemented
with B27, Glutamax I, Albumax, Pstrep and 7.0S nerve
growth factor (Wu et al., 2011). Medium was collected for
TNFsR enzyme-linked immunosorbent assay (ELISA) after
24-h culture.
2.6 Primary cell culture
E17 primary DRG neurons were isolated and cultured as
previously described (Wu et al., 2011). DRG neurons at 7
days in vitro were used in the studies. Enriched primary
satellite glial cells were prepared using a method described by
Arora et al. (2007) with minor modifications. The actual
procedures used for preparing enriched primary satellite glial
cells are given in Supporting Information Methods S1.
2.7 Behavioural testing
Mechanical and cold allodynia was measured using dynamic
plantar aesthesiometer and a method described by
Chattopadhyay et al. (2008) with slight modifications. The
detailed information for the testing is given in supporting
Information Methods S2 and S3.
2.8 Quantitative PCR
Total RNA isolation and quantitative PCR (qPCR) were con-
ducted as previously described (Wu et al., 2011). Primers
used for qPCR are given in Supporting Information Table S1.
mRNA levels were normalized to β-actin. mRNA amounts in
treatment groups were compared with the respective control
groups with the control mRNA level set at 1.
2.9 Biochemical analysis
Protein levels were analysed by Western blotting. Soluble
TNF-α and TNFsR in medium, and soluble TNF-α in DRG
lysates were determined by ELISA. TNF-α converting
enzyme (TACE) activity was evaluated as previously
described (Wu et al., 2011). Cellular source of protein
expression in DRG of animals was determined by immuno-
histochemistry. In situ hybridization of TNF-α mRNA was
carried out using the DIG DNA Labeling and Detection Kits
from Roche (Indianapolis, IN, USA) according to the manu-
facturer’s instructions. The detailed procedures for all the
assays and the information for the preparation of
digoxigenin-labelled TNF-α RNA for in situ hybridization are
described in Supporting Information Methods S4–S9.
2.10 Statistical analysis
In vitro experiments were repeated three times and the sta-
tistical significance of the difference between treatments was
determined by Student’s t-test. The statistical significance of
the difference between groups in animal studies was deter-
mined by analysis of variance (ANOVA) and corrected using
Bonferroni’s method. Results are expressed as mean ± SEM.
3. Results
3.1 Paclitaxel increases TNF-α mRNA and
enhances TACE activity resulting in TNF-α
cleavage in DRG
In order to explore the role of TNF-α in the pathogen-
esis of paclitaxel-induced neuropathic pain, we exam-
ined the effect of paclitaxel administration on the
expression and cleavage of TNF-α in the DRG of
animals. We modelled paclitaxel-induced painful
peripheral neuropathy by injecting rats with paclitaxel
(16 mg/kg, IP) once a week for 5 weeks (Authier et al.,
2000). Animals treated with paclitaxel developed
mechanical allodynia and cold allodynia that were
apparent at 2 weeks and persisted through 5 weeks of
paclitaxel treatment (Fig. 1) consistent with previous
weeks
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Figure 1 Paclitaxel-induced mechanical and cold allodynia. Paclitaxel-
induced neuropathic pain was modelled by repeated injection of pacli-
taxel as described in the Materials and methods section. Mechanical and
cold allodynia was evaluated 2 and 5weeks after the initiation of paclitaxel
treatment. Pain-related behaviours in paclitaxel-treated animals were
compared with those observed in vehicle-treated animals at each time
point. (A) Mechanical allodynia. (B) Cold allodynia. N = 10 animals per
group. *p ≤ 0.05; **p ≤ 0.01.
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reports (Authier et al., 2000). Animals receiving pacli-
taxel showed increased TNF-α mRNA in DRG at 2 and
5 weeks after the initiation of paclitaxel administration
compared with vehicle-treated animals (Fig. 2A). To
identify the cellular source of TNF-α mRNA expres-
sion, we performed in situ TNF-α mRNA hybridization
of DRG sections after 5 weeks of paclitaxel treatment.
TNF-α mRNA was localized predominantly in satellite
glial cells surrounding DRG neurons in paclitaxel-
treated animals (Fig. 2B). The increase in TNF-α
mRNA was reflected by an increase in sTNF-α without
accumulation of mTNF-α (Fig. 2C), suggesting that
most of the mTNF-α produced was cleaved into
sTNF-α. The increase in sTNF-α was confirmed by
ELISA (Fig. 2D), and correlated with an increase in
TACE activity in the DRG of paclitaxel-treated animals
(Fig. 2E).
3.2 Paclitaxel increases TRPA1 and TRPV4
expression in DRG neurons in animals
Previous work using knockout animals or channel
inhibitors indicates that TRPA1 is critical for the devel-
opment of paclitaxel-induced cold allodynia (Chen
et al., 2011; Materazzi et al., 2012), and both TRPA1
and TRPV4 contribute to paclitaxel-induced mechani-
cal allodynia (Alessandri-Haber et al., 2004). We
found a significant increase in the expression of
TRPA1 and TRPV4 at both mRNA and protein levels
measured by qPCR (Fig. 3A) and by Western blot
(Fig. 3B) in paclitaxel-treated animals after 2 and 5
weeks of treatment and confirmed by immunostaining
of DRG sections prepared from animals after 5 weeks
of treatment, which demonstrated TRPA1 localization
in a portion of medium and small neurons and TRPV4
expression in a portion of medium and large neurons
of DRG, respectively (Fig. 3C). Pre-incubation of the
antigen with the antibody prior to incubation of sec-
tions with the primary antibody resulted in no fluo-
rescent signals in sections prepared from both
paclitaxel and vehicle-treated animals (data not
shown) suggesting the specificity of the TRPA1 and
TRPV4 antibodies.
3.3 Inhibition of TNF-α signalling in vivo blocks
paclitaxel-induced increase in the expression
of TRPA1 and TRPV4 in DRG, and prevents
paclitaxel-induced pain
TNFsR is the truncated form of human p55 TNFR I
containing amino acids 1–211 of p55 TNFR I. TNFsR
competes with TNFR to bind to TNF-α, thus blocking
TNF-α signalling (Engelmann et al., 1990). We con-
structed an HSV vector vTNFsR that expresses TNFsR
and in vivo studies indicate that TNFsR is released into
the dorsal horn of spinal cord from primary afferent
terminals and blocks TNF-α signalling in spinal dorsal
horn (Peng et al., 2006; Hao et al., 2007). In order for
exploiting that vector to block TNF-α signalling in
DRG, we tested the release of TNFsR from soma after
expressed from DRG neurons from the vector.
Animals were injected with either vTNFsR or control
vector expressing green fluorescent protein (GFP) at
both hind paws. L4-6 DRGs from both hind legs were
dissected 3 days after vector inoculation, DRG neurons
partially dissociated and cultured. Medium was col-
lected after 24 h in vitro and TNFsR in the medium was
measured by ELISA. DRG neurons from animals trans-
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Figure 2 Paclitaxel-induced expression and
cleavage of TNF-α in satellite glial cells in DRG.
Paclitaxel-induced neuropathic pain was mod-
elled by repeated injection of paclitaxel. TNF-α
expression and TACE activity in DRG were
determined 2 and 5 weeks after the initiation
of paclitaxel treatment. (A) TNF-α qPCR. (B)
TNF-α in situ hybridization (arrows: satellite
glial cells; 5 weeks of paclitaxel). (C) Western
blot and quantification of sTNF-α (17 kD band).
(D) sTNF-α ELISA. (E) TACE activity. Comparison
between treatment and control groups was
made at each time point. n = 6 animals per
group for Western blot, ELISA and qPCR deter-
minations. *p ≤ 0.05; **p ≤ 0.01.
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fected with vTNFsE released into the medium
1.8 ± 0.09 ng/mL of TNFsR corresponding to 150 pg/
DRG neuron per day while TNFsR was below the
detection in the culture medium of DRG neurons
obtained from control vector-infected animals. The
results confirm that TNFsR is expressed and released
from DRG neurons transduced by vTNFsR in vivo. To
examine the role of TNF-α produced in DRG in the
pathogenesis of paclitaxel-induced pain, we tested the
effect of blocking TNF-α signalling on the expression
of TRPA1 and TRPV4 in DRG and on the development
of neuropathic pain in paclitaxel-treated animals.
vTNFsR was injected subcutaneously into both hind
foot paws 3 days before the start of paclitaxel admin-
istration and again 2 weeks later to ensure a robust
expression of TNFsR throughout the 5 weeks of pacli-
taxel treatment. Animals injected with vTNFsR but not
animals injected with the control vector expressing
GFP showed a substantial reduction in pain-related
behaviours at 2 and 5 weeks of paclitaxel treatment
(Fig. 4A). The reduction in pain-related behaviours
correlated with a blunting of the increase in the
expression of TRPA1 and TRPV4 mRNA (Fig. 4B) and
protein (Fig. 4C) in the DRG of paclitaxel-treated
animals inoculated with vTNFsR, an effect that was
not seen in paclitaxel-treated animals inoculated with
control vector.
3.4 Paclitaxel enhances the expression and
release of TNF-α from primary satellite glial
cells in a TLR-4-dependent manner
Because we found that paclitaxel induces the expres-
sion and cleavage of TNF-α in satellite glial cells in
animals and activation of TLR-4 is known to enhance
TNF-α expression and cleavage (Byrd-Leifer et al.,
2001), we examined the effect of paclitaxel on
the expression and release of TNF-α in enriched sat-
ellite glial cells in vitro. Enriched satellite glial cells
were prepared from DRG dissected from 17-day rat
embryos (Arora et al., 2007) and characterized by
co-expression of S100β and RAMP1 (Eftekhari et al.,
2010). TLR-4 protein was expressed in those cells and
the level of that expression was not changed by
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Figure 3 Paclitaxel increased the expression of TRPA1 and TRPV4 in DRG
in vivo. Paclitaxel-induced neuropathic pain was modelled by repeated
injection of paclitaxel. TRPA1 and TRPV4 expression in DRGwas evaluated
2 and 5 weeks after the initiation of paclitaxel treatment. Comparison
between treatment and control groups was made at each time point. (A)
TRPA1 and TRPV4 qPCR. (B) TRPA1 and TRPV4Western blot: Western blot
(upper) and quantification (lower). (C) Immunostaining for TRPA1 and
TRPV4 in DRG (5 weeks of paclitaxel). Arrowhead: medium and small
neurons for TRPA1; medium and large neurons for TRPV4. Star: large
neurons for TRPA1. Bar = 50 μm. n = 4 animals per group for immunohis-
tochemistry; n = 6 animals per group for Western blot and qPCR.
*p ≤ 0.05; **p ≤ 0.01.
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exposure to paclitaxel (Fig. 5A). However, exposure to
paclitaxel increased TNF-α mRNA (Fig. 5B) and
enhanced TNF-α release from those cells (Fig. 5C) in a
dose-dependent manner. Paclitaxel-induced enhance-
ment in TNF-α mRNA expression and TNF-α release
from those cells was blocked by co-treatment with the
TLR-4 antagonist TAK-242 (3 μmol/L) (Kawamoto
et al., 2008) (Fig. 5B and C).
3.5 Exposure to recombinant TNF-α increases
the expression of TRPA1 and TRPV4 in cultured
primary DRG neurons
To determine whether sTNF-α directly acts on DRG
neurons to increase the expression of TRPA1 and
TRPV4, we examined the effect of recombinant TNF-α
on the expression of TRPA1 and TRPV4 in primary
DRG neurons in culture. Exposure to recombinant
TNF-α increased TRPA1 and TRPV4 mRNA (Fig. 6A)
and protein (Fig. 6B) in primary DRG neurons in a
dose-dependent manner with the maximal effect
observed in cells exposed to 15 ng/mL of recombinant
TNF-α.
3.6 Paclitaxel does not increase TNF-α release
from primary DRG neurons in vitro and has
no effect on the expression of TRPA1 and
TRPV4 proteins
TLR-4 is also expressed in DRG neurons (Barajon
et al., 2009). To examine whether activation of TLR-4
in neurons contributes to paclitaxel-induced neuro-
pathic pain, we tested the effect of paclitaxel on the
release of TNF-α and on the protein expression of
TRPA1 and TRPV4 in cultured primary DRG neurons.
Paclitaxel treatment had no effect on the release of
TNF-α compared with control (Supporting Informa-
tion Fig. S1a), and no significant difference in TRPA1
and TRPV4 protein levels was observed in paclitaxel-
treated cells compared with control cells in the pres-
ence and the absence of TLR-4 antagonist TAK-242
(Supporting Information Fig. S1b).
4. Discussion
Our results suggest that paclitaxel, acting through
TLR-4, enhances the expression and cleavage of
TNF-α in satellite glial cells in DRG, and that release of
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Figure 4 TNFsR expressed and released from
an HSV vector in vivo prevented pain-related
behaviours and blocked the increases in TRPA1
and TRPV4. Paclitaxel-induced neuropathic
pain was modelled by repeated injection of
paclitaxel and TNFsR expressing vector vTNFsR
injected 3 days before the initiation of pacli-
taxel treatment and 2 weeks later. Pain-related
behaviours in animals and TRPA1 and TRPV4
expression in DRG were evaluated 2 and 5
weeks after the initiation of paclitaxel treat-
ment. Comparison between vTNFsR and
control vector-treated animals was made at
each time point. (A) Mechanical (left) and cold
allodynia (right). (B) TRPA1 and TRPV4 qPCR.
(C) TRPA1 and TRPV4 Western blot (upper) and
quantification (middle and lower). n = 10
animals per group for behavioural testing;
n = 4 animals per group for immunohistochem-
istry; n = 6 animals per group for mRNA and
protein analysis. *p ≤ 0.05; **p ≤ 0.01.
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sTNF-α from those cells increases expression of TRPA1
and TRPV4 in DRG neurons resulting in a phenotypic
change that causes neuropathic pain (Fig. 7).
Previous studies suggest the involvement of TNF-α
in the development of paclitaxel-induced pain
(Ledeboer et al., 2007; Cata et al., 2008). In the studies
we reported here, we found paclitaxel increased the
expression of TNF-α in DRG and that specifically
blocking TNF-α signalling by expressing TNFsR to
sequester TNF-α abrogated paclitaxel-induced pain.
Expression and release of TNFsR from DRG trans-
duced by vector vTNFsR in vivo does not alter pain-
related behaviours in naive animals (Hao et al., 2007).
These results confirm that TNF-α signalling is required
for the facilitation of paclitaxel-induced pain.
We found that the increased expression of TNF-α
was accompanied by enhanced activity of the TACE in
paclitaxel-treated animals leading to an increase in
TNF-α cleavage and release. These results indicate
sTNF-α is the functional form of TNF-α that signals to
cause pain in paclitaxel-treated animals. This is in con-
trast to the observation in neuropathic pain resulting
from physical nerve injury where up-regulated TNF-α
mRNA is reflected by a significant increase in mTNF-α
protein in DRG while no change in cleavage or
increase in release of TNF-α was seen (Schafers et al.,
2003; Sacerdote et al., 2008).
In situ hybridization showed that increased TNF-α
expression occurred in satellite glial cells in paclitaxel-
treated animals. Consistent with this in vivo observa-
tion, we found paclitaxel increased the expression and
release of TNF-α from enriched satellite glial cells in
culture, an effect that was blocked by TLR-4 inhibitor.
In contrast, paclitaxel had no effect on the expression
and release of TNF-α in primary DRG neurons in
culture. Although TLR-4 is constitutively expressed in
satellite glial cells and DRG neurons in animals
(Barajon et al., 2009), our results suggest that TLR-4
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Figure 5 Paclitaxel increased the expression and release of TNF-α in an
enriched satellite glial cell culture in vitro. Enriched satellite glial cell
culture was treated with paclitaxel of different concentrations in the pres-
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activation in satellite glial cells not in DRG neurons is
responsible for the elevated expression and cleavage of
TNF-α in paclitaxel-treated animals.
In order to understand how sTNF-α signalling leads
to cause pain in paclitaxel-treated animals, we tested
the effect of recombinant TNF-α on the expression of
TRP channel proteins TRPA1 and TRPV4 in primary
DRG neurons in culture. Genetic and pharmacological
studies indicate the roles of TRPA1 and TRPV4 in the
development of paclitaxel-induced pain (Alessandri-
Haber et al., 2004; Materazzi et al., 2012). Recombi-
nant TNF-α enhanced the expression of TRPA1 and
TRPV4 in primary DRG neurons in culture. In agree-
ment with the in vitro observations, we found in
animals that blocking TNF-α signalling through
expression of TNFsR in DRG from an HSV vector
blunted the increase in the expression of TRPA1 and
TRPV4 in DRG and abrogated paclitaxel-induced pain.
Taken together, our results suggest that sTNF-α pro-
duced in satellite glial cells gets involved in the patho-
genesis of paclitaxel-induced pain by up-regulating
the expression of channel proteins TRPA1 and TRPV4
in DRG neurons.
TACE is the major enzyme responsible for the cleav-
age of TNF-α. We found in our previous studies that
activation of TLR-4 by LPS up-regulates TACE expres-
sion and activity, thus resulting in cleavage and release
of TNF-α (Zhou et al., 2010). In the current study, we
found paclitaxel mimicked the activity of LPS to
enhance the expression and release of TNF-α via acti-
vation of TLR-4 in primary satellite glial cell culture
and in vivo studies indicated paclitaxel increased TACE
activity in DRG. These results point out enhanced
TACE activity observed in paclitaxel-treated animals
might result from direct activation of TLR-4 in satellite
glial cells by paclitaxel.
Paclitaxel inhibits axonal growth in DRG neurons in
a dose-dependent manner by TLR-4-dependent and
independent mechanisms (Ustinova et al., 2013).
However, it is unlikely that these neurotoxic effects of
paclitaxel on DRG neurons are related to the develop-
ment of pain because paclitaxel-induced pain appears
to be temporally independent of the development of
peripheral sensory neuropathy (Authier et al., 2000;
Dougherty et al., 2004), and we found no evidence of
a direct effect of paclitaxel on DRG expression of TRP
channels.
Recent studies show that paclitaxel may alter the
phenotype of neurons and glia through mechanisms
of action that differ depending on concentration. In
vitro, paclitaxel (10 nM) enhances TRPV1 agonist
(capsaicin)-evoked release of CGRP from DRG
neurons, while higher dose (300 nM) paclitaxel inhib-
its capsaicin-evoked release of CGRP (Pittman et al.,
2014). Whether paclitaxel alters channel function of
TRPA1 and TRPV4 in a similar fashion is not known.
Another study (Li et al., 2014) reported that low-dose
paclitaxel (1–2 mg/kg per dose) in vivo up-regulates
expression of TLR-4 in DRG neurons and in astrocytes
of the dorsal horn of spinal cord. We did not observe
any change in TLR-4 expression in animals treated
with high dose (16 mg/kg per dose; data not shown).
However, the observation by Li et al. (2014) that
intrathecal administration of a TLR-4 antagonist (LPS-
RS) reverses paclitaxel-induced pain is consistent with
the TLR-4-dependent mechanism of paclitaxel-
induced pain that we have proposed.
Several inflammatory cytokines including IL1β are
implicated in the pathogenesis of low-dose paclitaxel-
induced neuropathic pain in animals (Ledeboer et al.,
2007). We found that expression and release of TNFsR
from DRG neurons prevents high-dose paclitaxel-
induced pain in the current study, but the experiments
performed in this study do not rule out the possibility
that other inflammatory cytokines might be involved
in the pathogenesis of pain, as we and others have
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Figure 7 Schematic representation of the pro-
posed signalling pathway mediating paclitaxel-
induced neuropathic pain. Paclitaxel binding to
TLR-4 in satellite glial cells induces the expres-
sion of TNF-α and increases TACE activity
leading to release of sTNF-α (left), sTNF-α
binding to the TNF receptor enhances the
expression of TRPA1 and TRPV4 in DRG
neurons to cause pain (right).
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demonstrated that blocking TNF-α signalling by TNF-α
neutralizing antibody or by TNFsR expressed from an
HSV vector inhibits the expression not only of TNF-α
but also of other inflammatory cytokines (Hao et al.,
2007; Yamakawa et al., 2011).
4.1 Conclusion
In summary, the results presented herein suggest
paclitaxel activation of TLR-4 to cause release of
TNF-α from satellite glial cells increases expression of
TRPA1 and TRPV4 in neurons of the DRG to cause
neuropathic pain and that targeting either TLR-4,
TNF-α signalling or transient receptor potential
channel proteins may represent the strategies for
developing therapies for ameliorating neuropathic
pain in patients receiving paclitaxel therapy.
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